Loading...
•
Mar 30, 2024
Bioventus Q1 2024 Earnings Report
Reported strong first quarter with revenue growth and increased profitability, driven by Pain Treatments and Surgical Solutions, and raised full-year 2024 financial guidance reflecting enhanced revenue growth and strong execution of strategic priorities.
Key Takeaways
Bioventus reported a strong start to the year with an 8.7% increase in worldwide revenue, totaling $129.5 million, and a net loss from continuing operations of $6.0 million, which is an improvement compared to the prior-year period. The company's adjusted EBITDA from continuing operations increased by 33.5% to $22.6 million. Based on this momentum, Bioventus raised its full-year 2024 financial guidance.
Worldwide revenue totaled $129.5 million, an increase of 8.7% compared to the prior-year period.
On an organic basis, revenue increased 15.3%, driven by growth in Pain Treatments and Surgical Solutions.
Net loss from continuing operations was $6.0 million, compared to a net loss of $100.0 million in the prior-year period.
Adjusted EBITDA from continuing operations totaled $22.6 million, advancing 33.5% compared to the prior year.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Bioventus is raising financial guidance for full-year 2024.
Positive Outlook
- Net sales of $535 million to $550 million
- Adjusted EBITDA of $94 million to $99 million
- Non-GAAP EPS of $0.25 to $0.33
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...